The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.
The partners plan to apply genomics to traditional Chinese medicine.
The researchers said that better diagnostics are needed to distinguish between false preterm labor and true preterm labor to prevent unnecessary treatment.
The partners are initially planning to make searchable whole-genome data and EMRs from more than 1,000 rheumatoid arthritis patients accessible to trial developers.
The partners will use Hummingbird's miRNA database and expertise in sample preparation as well as BGI's BGISEQ sequencer and analysis pipeline to develop targeted miRNA IVD assays.
The funding is being provided by Genome Canada, as well as various Canadian provinces, businesses, and research institutes.
BGI is also developing sequencing-based self-sampling assays for pharmacogenomics and hereditary cancer testing.
The company recently released the MGISEQ-2000, MGISEQ-200, and MGIFLP sequencing platforms, as well as the MGIUS-R3 robotic ultrasound system.
The new agreement between the two companies commits to expanding the clinical genetic testing market in Turkey and is part of a global expansion for BGI.
The new institute, co-located with the China National GeneBank, will focus on synthetic biology technologies and applications.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.